Inside the skin, the cells that make collagen work while attached to a scaffold woven like a net. An ECM booster is a skin booster based on the idea of filling in the extracellular matrix (ECM) materials that make up that scaffold.
What Re2O injects is not living cells, but the scaffold left after the cells have been removed.
3-line summary
1. The process by which skin loses strength includes not only a decrease in collagen, but also a weakening of the scaffold that collagen-producing cells attach to and work on.
2. Re2O uses dermal tissue from which cells have been removed, taken from donated human skin, and is subject to the human-tissue safety management system.
3. In a comparative study in people, several skin measures were better than with conventional hyaluronic acid injections, but the study's scale and observation period were limited.
Why the scaffold inside the skin weakens
At the center of the scaffold inside the skin is collagen. Elastin, which helps the skin return to place, and hyaluronic acid, which holds moisture, are added to this and together they form the skin's structure.
When collagen bundles break into finer pieces with age, there is also less for collagen-producing cells to hold onto. These cells make less new collagen and release more of the substances that break down existing structure. The result is a vicious cycle in which remaining collagen also breaks more easily.
What Re2O injects
Even products that share the name skin booster differ in the material they inject and in their aim. Re2O is a product made by finely processing acellular dermal matrix (hADM), obtained by removing cells from donated human skin, so that it can be injected.
It is not a method that injects living cells. It uses the support material the cells were attached to, and is therefore distinguished from stem-cell procedures.
| Comparison item | Ingredient-focused booster | Re2O ECM booster |
|---|---|---|
| Material injected | A single ingredient or a combination, depending on the product | Finely processed acellular dermal matrix |
| Design focus | Uses the properties of the injected ingredient | Uses the scaffold material that makes up skin structure |
| Data to check | Data on that product and its ingredients | Studies of Re2O itself and the human-tissue management system |
Donated human tissue may be handled only by tissue banks licensed by Korea's MFDS, and this system manages the safety of donated tissue.
Findings confirmed in a comparative human study
Researchers injected Re2O and hyaluronic acid that had not been cross-linked, one on each side of the same person's face, then compared the changes.
| Comparison | Findings | Study scope |
|---|---|---|
| Re2O and non-cross-linked hyaluronic acid | On measurements of skin density, elasticity, wrinkles, pores, and hydration, the Re2O side was better. | 20 people were observed for 20 weeks. |
| Safety observations | No serious adverse events were reported. | This is a finding confirmed within the same study's participants and period. |
※ The study was small in scale and short in observation period, and among the authors was someone who served as an advisor to the manufacturer.
What to check during consultation
The name ECM booster alone does not make it clear which material is used. Checking the points below helps you distinguish the product's nature and its evidence.
- □ Confirm whether what is injected is a specific ingredient or a support material that makes up skin structure.
- □ Ask whether the material was obtained from human tissue or from another source.
- □ If it is human tissue, confirm that it passed through a licensed tissue bank.
- □ Check whether the results presented come from a study conducted in people.
- □ Along with the results, also confirm the number of participants and the observation period.
Frequently asked questions
Q1. Is an ECM booster a stem-cell procedure?
Re2O does not inject living cells. It uses the scaffold material left after cells are removed from donated skin tissue.
Q2. How does it differ from a hyaluronic acid booster?
Hyaluronic acid boosters use the properties of the injected ingredient. Re2O differs in that it uses acellular dermal matrix, in which several structural components remain, as a support material.
Q3. How is material that comes from another person's skin managed?
Donated human tissue is managed through tissue banks licensed by Korea's MFDS. During consultation, confirm both the material of the product used and whether it was managed by a tissue bank.
Q4. Is there a study that confirmed any changes?
A study that injected Re2O and non-cross-linked hyaluronic acid on opposite sides of the face measured skin density, elasticity, wrinkles, pores, and hydration. In that study, results were better on the side injected with Re2O.
Q5. How long do the effects last?
The study introduced here observed participants through 20 weeks after injection. That is the point at which the study finished its measurements, not a figure for how long results last after that.
Results, duration, and suitability vary with individual skin condition, age, and lifestyle, and the same outcome cannot be guaranteed.
Procedures may cause temporary redness or swelling, and contraindications may apply, so please confirm these during your consultation.
This article is general information and does not replace individual medical care. Please confirm diagnosis and treatment suited to your condition during a consultation.
Sources
- J Cell Commun Signal: PMID 29455303 — Source for ECM composition, the ratio of type I and III collagen, and the self-amplifying vicious cycle of aging in ‘Why the scaffold inside the skin weakens’
- International Journal of Molecular Sciences: PMC12985180 — Source for the study design, results, safety, limitations, and COI in ‘Findings confirmed in a comparative human study’
- Korean Law Information Center: Act on Safety and Management of Human Tissue, etc. · MFDS: Regulations on Tissue Bank Licensing and Human Tissue Safety Management, etc. — Source for the human-tissue management system in ‘What Re2O injects’
Related reading
Sources
- 진피 세포외기질과 노화: 콜라겐 원섬유 분절 기전 리뷰 (J Cell Commun Signal 2018, PMID 29455303)PubMed (Journal of Cell Communication and Signaling)
- 주입형 미립화 hADM 부스터 20주 split-face 임상 (Int J Mol Sci 2026, PMC12985180)PubMed Central (International Journal of Molecular Sciences)
- 인체조직안전 및 관리 등에 관한 법률국가법령정보센터
- 조직은행 허가 및 인체조직 안전관리 등에 관한 규정식품의약품안전처
Discuss options for your current needs
We review your current health and prior procedures before explaining appropriate options and their limits.



